SOS Small Cell Lung Cancer AECC
@sosclc-aecc.bsky.social
SOSCLC-AECC is a scientific network of biomedical researchers and clinicians with a focus on Small Cell Lung Cancer (SCLC) and neuroendocrine lung tumors. Coordinated by Luis Paz-Ares (H12O) and @mmalumbres.bsky.social @vhio.bsky.social, and funded by AECC
Pinned
A starter pack with researchers, clinicians, associations and patients wirh interest in Small Cell Lung Cancer #SCLC and related lung neuroendocrine tumors. Please contact us if interested in being included or have any suggestion go.bsky.app/HmjASG1
El cáncer de pulmón aumenta en mujeres y arrasa en España. En la red SOSCLC.ORG trabajaremos en las bases científicas y las implicaciones sociales de este problema!
www.eldiario.es/sociedad/can...
www.eldiario.es/sociedad/can...
El cáncer de pulmón en mujeres ya provoca casi tantas muertes como el de mama en España
Este año se diagnosticarán 296.103 nuevos casos de cáncer en España, un 3,29 % más que en 2024, según la estimación anual que hace la Sociedad Española de Oncología Médica (SEOM)
www.eldiario.es
February 1, 2025 at 7:37 AM
El cáncer de pulmón aumenta en mujeres y arrasa en España. En la red SOSCLC.ORG trabajaremos en las bases científicas y las implicaciones sociales de este problema!
www.eldiario.es/sociedad/can...
www.eldiario.es/sociedad/can...
Reposted by SOS Small Cell Lung Cancer AECC
2024 approvals: Summary of 14 new drugs/indications in #LungCancer by FDA
1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab (now SubQ)
9. #Ensartinib
#lcsm #OncSky #MedSky #Cancer
1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab (now SubQ)
9. #Ensartinib
#lcsm #OncSky #MedSky #Cancer
December 28, 2024 at 4:09 PM
2024 approvals: Summary of 14 new drugs/indications in #LungCancer by FDA
1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab (now SubQ)
9. #Ensartinib
#lcsm #OncSky #MedSky #Cancer
1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab (now SubQ)
9. #Ensartinib
#lcsm #OncSky #MedSky #Cancer
Reposted by SOS Small Cell Lung Cancer AECC
5 papers about Lung Cancer suggested by Stephen Liu
@stephenvliu.bsky.social
oncodaily.com/science/step...
#Cancer #GeorgetownUniversity #LungCancer #Nivolumab #NSCLC #OncoDaily #Oncology #Osimertinib #Health #PATHER2study #SCLC #TimeToxicity #Medicine
@stephenvliu.bsky.social
oncodaily.com/science/step...
#Cancer #GeorgetownUniversity #LungCancer #Nivolumab #NSCLC #OncoDaily #Oncology #Osimertinib #Health #PATHER2study #SCLC #TimeToxicity #Medicine
5 papers about Lung Cancer suggested by Stephen Liu - OncoDaily
5 papers about Lung Cancer suggested by Stephen Liu / Alessandro Brunelli, Anne Gulbech Ording, cancer, Dániel Sztankovics, Georgetown University, Jii Bum
oncodaily.com
December 28, 2024 at 4:54 PM
5 papers about Lung Cancer suggested by Stephen Liu
@stephenvliu.bsky.social
oncodaily.com/science/step...
#Cancer #GeorgetownUniversity #LungCancer #Nivolumab #NSCLC #OncoDaily #Oncology #Osimertinib #Health #PATHER2study #SCLC #TimeToxicity #Medicine
@stephenvliu.bsky.social
oncodaily.com/science/step...
#Cancer #GeorgetownUniversity #LungCancer #Nivolumab #NSCLC #OncoDaily #Oncology #Osimertinib #Health #PATHER2study #SCLC #TimeToxicity #Medicine
Reposted by SOS Small Cell Lung Cancer AECC
Our lab malumbreslab.org @vhio.bsky.social will join CIBERONC in 2025. Thanks for counting on us!! www.ciberonc.es/en
December 28, 2024 at 5:22 PM
Our lab malumbreslab.org @vhio.bsky.social will join CIBERONC in 2025. Thanks for counting on us!! www.ciberonc.es/en
@casanova-acebes.bsky.social, a member of the @sosclc-aecc.bsky.social, receives an ERC grant to improve cancer therapies! elpais.com/salud-y-bien...
Por qué es importante ajustar las terapias oncológicas a los ritmos circadianos de los pacientes
Las últimas investigaciones señalan el gran potencial terapéutico de la cronoterapia
elpais.com
December 23, 2024 at 7:48 AM
@casanova-acebes.bsky.social, a member of the @sosclc-aecc.bsky.social, receives an ERC grant to improve cancer therapies! elpais.com/salud-y-bien...
Our @sosclc-aecc.bsky.social researcher @crismayorruiz.bsky.social reports a new therapeutic strategy against #lung #cancer. A perfect example of the ideas to be developed within the #SCLC network! #oncosky #oncsky 🧪
Hi BlueSky world!
We are thrilled to share our new preprint around oncoprotein degradation in vivo —a fantastic collaboration with our friends in Salamanca #lab_santamaria #ciccancer! 😃
@irbbarcelona.bsky.social #TPD #KRAS
👇
www.biorxiv.org/content/10.1...
We are thrilled to share our new preprint around oncoprotein degradation in vivo —a fantastic collaboration with our friends in Salamanca #lab_santamaria #ciccancer! 😃
@irbbarcelona.bsky.social #TPD #KRAS
👇
www.biorxiv.org/content/10.1...
Targeted KRAS(G12V) degradation elicits efficient and durable lung adenocarcinoma regression in vivo
Recent drug discovery breakthroughs led to the approval of KRASG12C inhibitors in lung adenocarcinoma (LUAD). Unfortunately, clinical responses remain limited due to rapid resistance onset. Proteolysi...
www.biorxiv.org
December 17, 2024 at 5:51 PM
Our @sosclc-aecc.bsky.social researcher @crismayorruiz.bsky.social reports a new therapeutic strategy against #lung #cancer. A perfect example of the ideas to be developed within the #SCLC network! #oncosky #oncsky 🧪
Reposted by SOS Small Cell Lung Cancer AECC
Real-world analysis of 1L carboplatin, etoposide, atezolizumab for extensive stage #SCLC with ≥3y f/u published in Lung Cancer. In 207 pts, the 3y OS rate was 21%. Need to build on this backbone, but long-term survival is possible for some. #LCSM #OncSky
www.lungcancerjournal.info/article/S016...
www.lungcancerjournal.info/article/S016...
DEFINE_ME
www.lungcancerjournal.info
December 12, 2024 at 9:29 AM
Real-world analysis of 1L carboplatin, etoposide, atezolizumab for extensive stage #SCLC with ≥3y f/u published in Lung Cancer. In 207 pts, the 3y OS rate was 21%. Need to build on this backbone, but long-term survival is possible for some. #LCSM #OncSky
www.lungcancerjournal.info/article/S016...
www.lungcancerjournal.info/article/S016...
Reposted by SOS Small Cell Lung Cancer AECC
The OncoAlert 🚨Newsletter NOW OUT Covering September November 28-Dec 5, 2024
REGISTER AT www.OncoAlert360.com OR https://buff.ly/48Xpgz0
✅FDA Approves Duvalumab in #SCLC 🫁🇺🇸
✅FDA ACCELERATED APPROVAL TO
ZENOCUTUZUMAB-ZBCO IN #NSCLC 🫁
✅Lung adenocarcinomas with mucinous & more
REGISTER AT www.OncoAlert360.com OR https://buff.ly/48Xpgz0
✅FDA Approves Duvalumab in #SCLC 🫁🇺🇸
✅FDA ACCELERATED APPROVAL TO
ZENOCUTUZUMAB-ZBCO IN #NSCLC 🫁
✅Lung adenocarcinomas with mucinous & more
December 5, 2024 at 2:40 PM
The OncoAlert 🚨Newsletter NOW OUT Covering September November 28-Dec 5, 2024
REGISTER AT www.OncoAlert360.com OR https://buff.ly/48Xpgz0
✅FDA Approves Duvalumab in #SCLC 🫁🇺🇸
✅FDA ACCELERATED APPROVAL TO
ZENOCUTUZUMAB-ZBCO IN #NSCLC 🫁
✅Lung adenocarcinomas with mucinous & more
REGISTER AT www.OncoAlert360.com OR https://buff.ly/48Xpgz0
✅FDA Approves Duvalumab in #SCLC 🫁🇺🇸
✅FDA ACCELERATED APPROVAL TO
ZENOCUTUZUMAB-ZBCO IN #NSCLC 🫁
✅Lung adenocarcinomas with mucinous & more
Reposted by SOS Small Cell Lung Cancer AECC
A starter pack with researchers, clinicians, associations and patients wirh interest in Small Cell Lung Cancer #SCLC and related lung neuroendocrine tumors. Please contact us if interested in being included or have any suggestion go.bsky.app/HmjASG1
December 8, 2024 at 8:28 PM
A starter pack with researchers, clinicians, associations and patients wirh interest in Small Cell Lung Cancer #SCLC and related lung neuroendocrine tumors. Please contact us if interested in being included or have any suggestion go.bsky.app/HmjASG1
Reposted by SOS Small Cell Lung Cancer AECC
Living with lung cancer isn’t just about battling a disease; it’s about navigating an entirely different reality. These quotes are a glimpse into the struggles, fears, and uncertainties faced by those living with young lung cancer every day. 💔
#LivingWithLungCancer #CancerAdvocacy #lcsm
#LivingWithLungCancer #CancerAdvocacy #lcsm
December 10, 2024 at 11:12 PM
Living with lung cancer isn’t just about battling a disease; it’s about navigating an entirely different reality. These quotes are a glimpse into the struggles, fears, and uncertainties faced by those living with young lung cancer every day. 💔
#LivingWithLungCancer #CancerAdvocacy #lcsm
#LivingWithLungCancer #CancerAdvocacy #lcsm
@sosclc-aecc.bsky.social researcher Dolores Isla talks in El Mundo about current challenges in lung cancer..
Por si fuera de interés, escribo en El Mundo sobre avances y retos en cáncer de pulmón, en una conversación con la doctora Dolores Isla
www.elmundo.es/uestudio/202...
www.elmundo.es/uestudio/202...
Cáncer de pulmón: grandes avances, persisten los retos
La doctora Dolores Isla es una de las principales expertas en este ámbito. Es presidenta de la Asociación para la Investigación del Cáncer de Pulmón en Mujeres (Icapem) y jefa...
www.elmundo.es
December 9, 2024 at 7:02 AM
@sosclc-aecc.bsky.social researcher Dolores Isla talks in El Mundo about current challenges in lung cancer..
Reposted by SOS Small Cell Lung Cancer AECC
A starter pack with researchers, clinicians, associations and patients wirh interest in Small Cell Lung Cancer #SCLC and related lung neuroendocrine tumors. Please contact us if interested in being included or have any suggestion go.bsky.app/HmjASG1
December 8, 2024 at 8:31 PM
A starter pack with researchers, clinicians, associations and patients wirh interest in Small Cell Lung Cancer #SCLC and related lung neuroendocrine tumors. Please contact us if interested in being included or have any suggestion go.bsky.app/HmjASG1
December 8, 2024 at 8:28 PM
A starter pack with researchers, clinicians, associations and patients wirh interest in Small Cell Lung Cancer #SCLC and related lung neuroendocrine tumors. Please contact us if interested in being included or have any suggestion go.bsky.app/HmjASG1
Reposted by SOS Small Cell Lung Cancer AECC
Why #lungcancer (the #1 cancer killer) needs more funding and research:
Only 2 of the 7 LC patient advocates in this 2018 photo are still alive (including me). While newer treatments like targeted therapy and immune checkpoint inhibitors are effective for some, they don't work for all. #LCSM
Only 2 of the 7 LC patient advocates in this 2018 photo are still alive (including me). While newer treatments like targeted therapy and immune checkpoint inhibitors are effective for some, they don't work for all. #LCSM
December 7, 2024 at 5:29 PM
Why #lungcancer (the #1 cancer killer) needs more funding and research:
Only 2 of the 7 LC patient advocates in this 2018 photo are still alive (including me). While newer treatments like targeted therapy and immune checkpoint inhibitors are effective for some, they don't work for all. #LCSM
Only 2 of the 7 LC patient advocates in this 2018 photo are still alive (including me). While newer treatments like targeted therapy and immune checkpoint inhibitors are effective for some, they don't work for all. #LCSM
New therapies in SCLC: FDA approves durvalumab for limited-stage small cell lung cancer
www.fda.gov/drugs/resour...
www.fda.gov/drugs/resour...
FDA approves durvalumab for limited-stage small cell lung cancer
On December 4, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) for limited-stage small cell lung cancer (LS-SCLC).
www.fda.gov
December 5, 2024 at 4:40 PM
New therapies in SCLC: FDA approves durvalumab for limited-stage small cell lung cancer
www.fda.gov/drugs/resour...
www.fda.gov/drugs/resour...
An insightful review on genetics and resistance to immunotherapies in cancer by @sosclc-aecc.bsky.social researcher @franmj88.bsky.social @vhio.bsky.social www.cell.com/trends/cance...
December 5, 2024 at 4:38 PM
An insightful review on genetics and resistance to immunotherapies in cancer by @sosclc-aecc.bsky.social researcher @franmj88.bsky.social @vhio.bsky.social www.cell.com/trends/cance...
Reposted by SOS Small Cell Lung Cancer AECC
2 new studies in Nature reveal how isoprene—a gas from plants—forms particles in the upper atmosphere, improving climate models. Better understanding of air quality & particle behaviour could aid future research into impacts on lung health inclu. #lungcancer #LCSM
www.nature.com/nature/volum...
www.nature.com/nature/volum...
December 5, 2024 at 7:42 AM
2 new studies in Nature reveal how isoprene—a gas from plants—forms particles in the upper atmosphere, improving climate models. Better understanding of air quality & particle behaviour could aid future research into impacts on lung health inclu. #lungcancer #LCSM
www.nature.com/nature/volum...
www.nature.com/nature/volum...